SCHEMBL25966752

SCHEMBL25966752

CCn1nc2ccccc2c1C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 9/20 0.45
ATM Q13315 2/20 0.43
SLC9A1 P19634 1/20 0.41
KAT2B Q92831 1/20 0.37
KDM4E B2RXH2 2/20 0.36
USP2 O75604 2/20 0.36
CASP1 P29466 2/20 0.36
CASP7 P55210 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 1/20 0.36
TNNI3 P19429 1/20 0.36
CRHBP P24387 1/20 0.36
MAPK1 P28482 1/20 0.36
TNNT2 P45379 1/20 0.36
TNNC1 P63316 1/20 0.36
KMT2A Q03164 1/20 0.36
CRHR2 Q13324 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
TLR9 Q9NR96 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25966748 0.78 HASPIN (0.38)
SCHEMBL25966750 0.78 HASPIN (0.35) ATMKAT2B
SCHEMBL10129331 0.76 ADORA3 (0.43) MPOATMSLC9A1KDM4ECASP1
SCHEMBL5763004 0.76 MPO (0.46) MPOATMSLC9A1KDM4EUSP2
SCHEMBL25966751 0.75 TLR8 (0.35) MPOATMSLC9A1KAT2BKDM4E
SCHEMBL25966746 0.75 HTR2C (0.35) MPOKAT2BKDM4EL3MBTL1NPC1
SCHEMBL25153638 0.74 MPO (0.45) MPOATMSLC9A1KDM4EUSP2
SCHEMBL11812180 0.74 ILK (0.48) MPOATMSLC9A1KDM4EUSP2
SCHEMBL2272687 0.74 MPO (0.45) MPOATMSLC9A1KDM4EUSP2
SCHEMBL14754847 0.74 MPO (0.45) MPOATMSLC9A1KDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MPO 1755/4885ATM 110/4885SLC9A1 1066/4885
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MPO 1788/4885ATM 112/4885SLC9A1 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.